Literature DB >> 1486194

Treatment of hepatic encephalopathy with non-absorbable antibiotics.

D Festi1, G Mazzella, P Parini, M Ronchi, A Cipolla, M Orsini, A Sangermano, F Bazzoli, R Aldini, E Roda.   

Abstract

Hepatic encephalopathy represents a well known neuropsychiatric syndrome in patients with either acute or chronic impaired liver function and is characterized by disturbance of consciousness, personality and intellectual capacity, altered neuromuscular activity and electroencephalographic abnormalities. The pathogenesis of the syndrome is still unknown, although important roles are ascribed to circulating gut-derived toxins of nitrogenous origin and to changing in central neurotransmission. Therefore, treatment is aimed to reduce the production and absorption of gut-derived toxins and to modify central neurotransmission balance. Among the different therapeutic approaches proposed for the management of hepatic encephalopathy, antimicrobial agents, alone or in combination with non-absorbable disaccharides, represent an important step, being able to reduce the production and absorption of ammonia, a compound of key importance in the pathogenesis of hepatic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486194

Source DB:  PubMed          Journal:  Ital J Gastroenterol        ISSN: 0392-0623


  3 in total

1.  Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.

Authors:  Yong Han Paik; Kwan Sik Lee; Kwang Hyub Han; Kun Hoon Song; Myoung Hwan Kim; Byung Soo Moon; Sang Hoon Ahn; Se Joon Lee; Hyo Jin Park; Dong Ki Lee; Chae Yoon Chon; Sang In Lee; Young Myoung Moon
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

Review 2.  Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

3.  Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.

Authors:  Steliana Huhulescu; Ulrich Sagel; Anita Fiedler; Verena Pecavar; Marion Blaschitz; Guenther Wewalka; Franz Allerberger; Alexander Indra
Journal:  J Med Microbiol       Date:  2011-02-03       Impact factor: 2.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.